How is bepirovirsen (Hebsago) better than other hepatitis B antiviral agents?

Bepirovirsen Does Not Outperform Standard Hepatitis B Therapies

Bepirovirsen (Hebsago) is not better than established hepatitis B medications—it achieves functional cure in only 9-20% of patients compared to the 90%+ viral suppression rates with entecavir or tenofovir, and it requires injections with significant side effects including ALT elevations and injection-site reactions. 1, 2

Current Standard of Care Remains Superior

The established first-line therapies for chronic hepatitis B are entecavir, tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF), which are recommended by all major guidelines 3, 4, 5, 6. These agents:

• Achieve >90% viral suppression (undetectable HBV DNA) after 3 years in treatment-adherent patients 5
• Have high genetic barriers to resistance (entecavir: 1.2% resistance at 5 years; tenofovir: no resistance reported at 1.5 years) 7
• Are oral medications taken once daily with excellent long-term safety profiles 3, 4
• Demonstrate regression of fibrosis and reversal of cirrhosis with prolonged use 5, 8

Bepirovirsen's Limited Efficacy

The phase 3 B-Well trials showed bepirovirsen achieved functional cure (sustained HBV DNA <LLOQ and HBsAg loss for ≥24 weeks) in only:

• 20% of patients in B-Well 1 (127/650 patients)
• 19% of patients in B-Well 2 (106/570 patients)
• 0% in placebo groups 1

The earlier phase 2b B-Clear trial was even less impressive, with functional cure rates of only 9-10% among patients receiving the optimal 300mg weekly dose for 24 weeks 2.

Critical Limitations

Bepirovirsen only works in a narrow patient subset: All responders in clinical trials had baseline HBsAg levels ≤3,000 IU/mL 9. This excludes the majority of chronic hepatitis B patients who have higher HBsAg levels.

High relapse rates: The B-Together study investigating sequential bepirovirsen followed by peginterferon was specifically designed to address the "relapse rates previously observed with bepirovirsen alone" 9, indicating that even among initial responders, durability is problematic.

Significant Safety Concerns

Bepirovirsen carries a substantially worse side effect profile than standard oral antivirals:

During Treatment Period (Weeks 1-24):

• 91% experienced adverse events vs 73% with placebo 1
• 16% had grade 3+ adverse events vs 3% with placebo 1
• 6% had grade 3 ALT elevations 1
• Common side effects: injection-site reactions, pyrexia, fatigue, increased ALT 2

Mechanism of ALT Elevations

Post-hoc analyses suggest the ALT increases reflect bepirovirsen-induced immune-mediated killing of infected hepatocytes 10. While this may be part of the therapeutic mechanism, it creates clinical management challenges and potential hepatotoxicity concerns that don't exist with standard oral antivirals.

Administration Burden

Bepirovirsen requires weekly subcutaneous injections for 24 weeks (with loading doses on days 4 and 11) 1, 2, compared to once-daily oral pills for entecavir/tenofovir. This represents a significant treatment burden and adherence challenge.

When Bepirovirsen Might Be Considered

The only theoretical advantage of bepirovirsen is the potential for finite-duration therapy leading to functional cure (HBsAg loss), which standard oral antivirals rarely achieve (<5% at 12 months) 11. However, this benefit materializes in fewer than 1 in 5 patients, and only in those with:

• Baseline HBsAg ≤3,000 IU/mL
• Willingness to accept weekly injections
• Tolerance for significant side effects including ALT flares
• Already on stable nucleos(t)ide analogue therapy 1, 9

Clinical Algorithm

For treatment-naive patients or those requiring long-term viral suppression:

• Start entecavir 0.5mg daily OR tenofovir (TDF 300mg or TAF 25mg) daily 3, 4, 5
• These achieve >90% viral suppression with minimal side effects
• Continue indefinitely until HBsAg loss (rare) or as clinically indicated

Bepirovirsen should NOT be used as first-line therapy given its:

• Lower efficacy (20% functional cure vs 90%+ suppression with standard therapy)
• Higher adverse event rates (91% vs standard therapy's excellent tolerability)
• Injection requirement vs oral administration
• Restriction to patients with low HBsAg levels

Potential future role (investigational): In highly selected patients with HBsAg <3,000 IU/mL on stable NA therapy who strongly desire finite therapy and accept the 80% failure rate and significant side effects, bepirovirsen could be considered as part of clinical trials or expanded access programs.

Common Pitfalls to Avoid

1. Don't confuse "functional cure" rates with viral suppression rates: 20% functional cure sounds promising until you realize standard therapy achieves 90%+ viral suppression
2. Don't overlook the patient selection bias: Trial participants were already on stable NA therapy with specific HBsAg thresholds
3. Don't minimize the ALT elevations: While potentially mechanistic, grade 3 ALT increases in 6% of patients require careful monitoring and may indicate hepatotoxicity 1

The evidence clearly demonstrates that entecavir and tenofovir remain the gold standard for chronic hepatitis B treatment, with bepirovirsen representing an investigational option with limited applicability and inferior overall efficacy-to-safety profile 3, 4, 5, 6, 1.